Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders

Area of Science:

• Immunology
• Infectious Diseases
• Hematology

Background:

• Primary immunodeficiency disorders (PID) are genetic conditions causing severe, recurrent infections.
• Chronic viral infections pose significant risks for PID patients, particularly before and after hematopoietic stem cell transplantation (HSCT).
• Current antiviral therapies are often costly, toxic, and may be ineffective against drug-resistant viruses.

Purpose of the Study:

• To review the potential of adoptive immunotherapy using virus-specific T lymphocytes (VSTs) for PID patients.
• To discuss the generation methods, clinical applications, and limitations of VSTs in PID.
• To explore future directions for broadening VST applicability in PID management.

Main Methods:

• Review of existing literature on VST generation and clinical trials in PID.
• Analysis of VST efficacy and safety data in PID patients, both pre- and post-HSCT.
• Discussion of challenges and potential advancements in VST-based adoptive immunotherapy.

Main Results:

• VSTs have shown promise as a therapeutic option for PID patients with refractory viral infections.
• Previous phase I trials have established the feasibility of VST use in PID patients post-HSCT.
• VSTs may offer a viable alternative or adjunct to conventional therapies, potentially before HSCT.

Conclusions:

• Adoptive immunotherapy with VSTs is an attractive strategy for PID patients with impaired T cell immunity and chronic viral infections.
• Further research and development are needed to optimize VST generation and expand their clinical use in PID.
• VSTs represent a significant advancement in managing complex viral infections in immunocompromised individuals.